NCT01593787 - Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Hypertension With Renal Dysfunction

Interventions

DRUG

LCZ696

100 mg, 200 mg, 400 mg tablets.

Trial Locations (13)

Novartis Investigative Site, Sapporo

Novartis Investigative Site, Sapporo

Novartis Investigative Site, Sapporo

Novartis Investigative Site, Aira

Novartis Investigative Site, Kawasaki

Novartis Investigative Site, Yokohama

Novartis Investigative Site, Sendai

Novartis Investigative Site, Kurashiki

Novartis Investigative Site, Osaka

Novartis Investigative Site, Fujimino

Novartis Investigative Site, Hachiōji

Novartis Investigative Site, Minato-ku

Novartis Investigative Site, Shinagawa-ku